William Guyer - Jul 1, 2024 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.
Stock symbol
CORT
Transactions as of
Jul 1, 2024
Transactions value $
-$108,400
Form type
4
Date filed
7/3/2024, 05:13 PM
Previous filing
Jun 5, 2024
Next filing
Aug 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $217K +10K +165.59% $21.65 16K Jul 1, 2024 Direct F1
transaction CORT Common Stock Sale -$325K -10K -62.35% $32.49 6.04K Jul 1, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -10K -2% $0.00 490K Jul 1, 2024 Common Stock 10K $21.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
F3 Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.